Sign in

    Yun Jung

    Research Analyst at Wedbush Securities

    Yun Zhong, Ph.D., is a Senior Vice President, Equity Research Analyst at Wedbush Securities, specializing in biotechnology with a focus on gene therapy, orphan diseases, and genetic medicine. He currently covers companies such as Ascendis Pharma, BioMarin Pharmaceuticals, Keros Therapeutics, MoonLake Immunotherapeutics, Passage Bio, Protagonist Therapeutics, Rezolute, Rocket Pharmaceuticals, Voyager Therapeutics, and Wave Life Sciences, and has initiated coverage on these high-profile biotech firms since joining Wedbush in 2024. Dr. Zhong began his career at Cowen and Company and has held senior analyst roles at SunTrust Robinson Humphrey, BTIG, Berenberg Capital Markets, Janney Montgomery Scott, and Jefferies, bringing over a decade of experience to his current leadership role. He holds a PhD in neuroscience and molecular biology from Rockefeller University, earned MS and BS degrees in biophysical engineering from Osaka University, and maintains FINRA registration for equity research.

    Yun Jung's questions to Wave Life Sciences (WVE) leadership

    Yun Jung's questions to Wave Life Sciences (WVE) leadership • Q1 2025

    Question

    An analyst from Wedbush Securities questioned the rationale for splitting the AATD data release into two separate announcements (Q3 and Fall) and asked if the DMD NDA submission would include monthly dosing data.

    Answer

    President and CEO Dr. Paul Bolno clarified that the company will release the 200mg multi-dose AATD data as soon as it is complete because it is a material dataset, rather than hold it for the 400mg cohort data. He noted the 400mg cohort is enrolling well, so the timelines could potentially converge. For the DMD program, he confirmed the plan is to include monthly dosing data in the 2026 NDA submission to support a monthly regimen on the label at launch.

    Ask Fintool Equity Research AI